BA, Harvard University
M.D., University of Miami, School of Medicine
Ph.D., Harvard University
Relapse remains a major issue following an autologous transplant. Relapses result from either the infusion of contaminating tumor cells in the stem cell product and/or from the incomplete eradication of endogenous malignant cells by the transplant conditioning regimens. Directly following an autologous transplant, the immune system is relatively incompetent and this immune incompetence may contribute to the high relapse rates seen after autologous transplantation.
My clinical research interests have focused on trying to augment the immune system after an autologous transplant. A number of clinical trials using different approaches have been developed. Treating with immunological and non-immunological therapies posttransplant can possibly change the time to relapse and prolong survival.